Dr. Halene received her MD and PhD from Eberhard-Karls-Universitat Tubingen. Her laboratory focuses focuses on the study of myeloid malignancies and hematopoiesis. In particular, she seeks to understand the role of mutations in splicing factors, present in nearly 50% of patient with Myelodysplasia (MDS) and Acute Myeloid Leukemia (AML). In addition, the laboratory seeks to establish a “co-clinical” model for MDS and AML with the goal to facilitate the translation of improved, less toxic, and more efficient treatments for MDS and AML into the clinic.